Technical Analysis for HURA - TuHURA Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 20 DMA Resistance | Bearish | 7.03% | |
| Fell Below 200 DMA | Bearish | 7.03% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 7.03% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 7.03% | |
| Wide Bands | Range Expansion | 7.03% | |
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% |
| Alert | Time |
|---|---|
| 20 DMA Resistance | about 22 hours ago |
| Up 5% | about 23 hours ago |
| Rose Above 20 DMA | about 23 hours ago |
| Rose Above 200 DMA | about 23 hours ago |
| 60 Minute Opening Range Breakout | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 10/09/2024
TuHURA Biosciences, Inc. Description
TuHURA Biosciences is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced Merkel Cell Carcinoma. In addition, TuHURA is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Immune System Immunotherapy Tumor Cancer Immunotherapy Antineoplastic Drugs Checkpoint Inhibitor Tumor Microenvironment Pembrolizumab Adjunctive Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 23.73 |
| 52 Week Low | 2.835 |
| Average Volume | 101,547 |
| 200-Day Moving Average | 6.01 |
| 50-Day Moving Average | 6.29 |
| 20-Day Moving Average | 6.12 |
| 10-Day Moving Average | 5.32 |
| Average True Range | 0.82 |
| RSI (14) | 43.82 |
| ADX | 43.05 |
| +DI | 14.77 |
| -DI | 22.20 |
| Chandelier Exit (Long, 3 ATRs) | 5.95 |
| Chandelier Exit (Short, 3 ATRs) | 6.95 |
| Upper Bollinger Bands | 8.11 |
| Lower Bollinger Band | 4.13 |
| Percent B (%b) | 0.49 |
| BandWidth | 64.95 |
| MACD Line | -0.28 |
| MACD Signal Line | -0.28 |
| MACD Histogram | -0.0041 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.92 | ||||
| Resistance 3 (R3) | 6.85 | 6.49 | 6.78 | ||
| Resistance 2 (R2) | 6.49 | 6.28 | 6.53 | 6.74 | |
| Resistance 1 (R1) | 6.29 | 6.15 | 6.39 | 6.37 | 6.69 |
| Pivot Point | 5.94 | 5.94 | 5.99 | 5.98 | 5.94 |
| Support 1 (S1) | 5.74 | 5.73 | 5.84 | 5.81 | 5.49 |
| Support 2 (S2) | 5.38 | 5.60 | 5.42 | 5.44 | |
| Support 3 (S3) | 5.18 | 5.38 | 5.40 | ||
| Support 4 (S4) | 5.26 |
